Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have received a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $26.14.

A number of analysts have recently commented on the company. Wedbush reissued an “outperform” rating and issued a $22.84 price objective (down previously from $25.00) on shares of Syros Pharmaceuticals in a research note on Thursday, August 10th. JMP Securities downgraded Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Cowen Inc reissued a “buy” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Cann reissued a “buy” rating and issued a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, August 21st. Finally, Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th.

Shares of Syros Pharmaceuticals (SYRS) traded up $0.21 during mid-day trading on Friday, reaching $13.75. The company’s stock had a trading volume of 102,716 shares, compared to its average volume of 92,280. Syros Pharmaceuticals has a one year low of $10.22 and a one year high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.53). sell-side analysts expect that Syros Pharmaceuticals will post -2.09 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors raised its position in shares of Syros Pharmaceuticals by 249.8% during the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $133,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $149,000. The Manufacturers Life Insurance Company raised its position in shares of Syros Pharmaceuticals by 11,253.8% during the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock worth $170,000 after purchasing an additional 10,466 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Syros Pharmaceuticals during the first quarter worth $185,000. 55.19% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/syros-pharmaceuticals-inc-syrs-given-average-rating-of-buy-by-brokerages/1724715.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.